Cardiol Therapeutics’ MAVERIC Trial Hits 75% Enrollment, Expands to 25 U.S. Sites
Cardiol Therapeutics has expanded its U.S. Phase III MAVERIC trial network to leading centers such as Cleveland Clinic and Mayo Clinic campuses, raising patient enrollment from 50% to 75% and planning up to 25 sites by Q3 2026. The pivotal trial aims to enroll ~110 recurrent pericarditis patients by end-Q2 2026 to support an NDA with FDA.
1. Expansion of MAVERIC Trial Network
Cardiol Therapeutics has expanded the U.S. MAVERIC Phase III trial network to leading cardiovascular centers including Cleveland Clinic, three Mayo Clinic campuses, Northwestern University, Massachusetts General Hospital and others, with up to seven additional sites planned to bring the total to 25 clinical centers.
2. Enrollment Milestones
Patient enrollment has accelerated from 50% in early January to 75% as of late April, with a target of enrolling approximately 110 recurrent pericarditis patients by the end of Q2 2026 and potential extension into Q3 to accommodate enrollment at new sites.
3. Trial Objectives and Regulatory Path
The randomized, double-blind, placebo-controlled MAVERIC trial is designed to generate pivotal data to support a New Drug Application for CardiolRx™ with the U.S. FDA, building on Phase II results that demonstrated rapid and sustained reductions in pericarditis pain and inflammation.
4. Market Opportunity in Recurrent Pericarditis
Recurrent pericarditis affects an estimated 40,000 U.S. patients annually, driving hospitalization costs of $20,000–$30,000 per stay and highlighting an unmet need for non-immunosuppressive oral therapies that CardiolRx™ aims to address.